149 related articles for article (PubMed ID: 33222769)
1. Assessment of practices for suspended oral drugs by tablet crushing in pediatric units.
Nguyen D; Secretan PH; Auvity S; Vidal F; Postaire M; Cisternino S; Schlatter J
Eur J Pharm Biopharm; 2020 Dec; 157():175-182. PubMed ID: 33222769
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of crushed ticagrelor tablet doses: recovery following crushing and naso-gastric tube passage ex vivo.
Crean B; Finnie C; Crosby A
Drugs R D; 2013 Jun; 13(2):153-7. PubMed ID: 23737454
[TBL] [Abstract][Full Text] [Related]
3. Drug loss while crushing tablets: Comparison of 24 tablet crushing devices.
Thong MY; Manrique YJ; Steadman KJ
PLoS One; 2018; 13(3):e0193683. PubMed ID: 29494695
[TBL] [Abstract][Full Text] [Related]
4. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.
Pabari RM; McDermott C; Barlow J; Ramtoola Z
Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007
[TBL] [Abstract][Full Text] [Related]
5. Impact of recommendations on crushing medications in geriatrics: from prescription to administration.
Bourdenet G; Giraud S; Artur M; Dutertre S; Dufour M; Lefèbvre-Caussin M; Proux A; Philippe S; Capet C; Fontaine-Adam M; Kadri K; Landrin I; Gréboval E; Touflet M; Nanfack J; Tharasse C; Varin R; Rémy E; Daouphars M; Doucet J
Fundam Clin Pharmacol; 2015 Jun; 29(3):316-20. PubMed ID: 25789404
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical and safety considerations of tablet crushing in patients undergoing enteral intubation.
Salmon D; Pont E; Chevallard H; Diouf E; Tall ML; Pivot C; Pirot F
Int J Pharm; 2013 Feb; 443(1-2):146-53. PubMed ID: 23299084
[TBL] [Abstract][Full Text] [Related]
7. Is there variability in drug release and physical characteristics of amiodarone chloride from different commercially available tablets? Possible therapeutic implications.
Ngo SN; Barnes T
Int J Pharm Pract; 2010 Aug; 18(4):245-8. PubMed ID: 20636678
[TBL] [Abstract][Full Text] [Related]
8. The BioGIT System: a Valuable In Vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration.
Kourentas A; Vertzoni M; Barmpatsalou V; Augustijns P; Beato S; Butler J; Holm R; Ouwerkerk N; Rosenberg J; Tajiri T; Tannergren C; Symillides M; Reppas C
AAPS J; 2018 May; 20(4):71. PubMed ID: 29797293
[TBL] [Abstract][Full Text] [Related]
9. Pediatric drugs--a review of commercially available oral formulations.
Strickley RG; Iwata Q; Wu S; Dahl TC
J Pharm Sci; 2008 May; 97(5):1731-74. PubMed ID: 17823956
[TBL] [Abstract][Full Text] [Related]
10. Disintegration of chemotherapy tablets for oral administration in patients with swallowing difficulties.
Siden R; Wolf M
J Oncol Pharm Pract; 2013 Jun; 19(2):145-50. PubMed ID: 22907947
[TBL] [Abstract][Full Text] [Related]
11. Novel chewable sustained-release tablet containing verapamil hydrochloride.
El-Gazayerly ON; Rakkanka V; Ayres JW
Pharm Dev Technol; 2004; 9(2):181-8. PubMed ID: 15202577
[TBL] [Abstract][Full Text] [Related]
12. Crushed tablets: does the administration of food vehicles and thickened fluids to aid medication swallowing alter drug release?
Manrique YJ; Lee DJ; Islam F; Nissen LM; Cichero JA; Stokes JR; Steadman KJ
J Pharm Pharm Sci; 2014; 17(2):207-19. PubMed ID: 24934549
[TBL] [Abstract][Full Text] [Related]
13. The accuracy and precision of measuring Lorazepam from three liquid preparations.
Lee WM; Lugo RA; Cash J; Rusho WJ; Mackay M; Welkie K
J Pediatr Pharmacol Ther; 2005 Jan; 10(1):36-42. PubMed ID: 23118624
[TBL] [Abstract][Full Text] [Related]
14. Stability of hydrocortisone oral suspensions prepared from tablets and powder.
Fawcett JP; Boulton DW; Jiang R; Woods DJ
Ann Pharmacother; 1995 Oct; 29(10):987-90. PubMed ID: 8845559
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the bioequivalence of montelukast chewable tablets after a single oral administration using a validated LC-MS/MS method.
Zaid AN; Abualhasan MN; Watson DG; Mousa A; Ghazal N; Bustami R
Drug Des Devel Ther; 2015; 9():5315-21. PubMed ID: 26451086
[TBL] [Abstract][Full Text] [Related]
16. How close is the dose? Manipulation of 10 mg hydrocortisone tablets to provide appropriate doses to children.
Watson C; Webb EA; Kerr S; Davies JH; Stirling H; Batchelor H
Int J Pharm; 2018 Jul; 545(1-2):57-63. PubMed ID: 29705101
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical characterisation of fluids and soft foods frequently mixed with oral drug formulations prior to administration to children.
Kersten E; Barry A; Klein S
Pharmazie; 2016 Mar; 71(3):122-7. PubMed ID: 27183705
[TBL] [Abstract][Full Text] [Related]
18. Primary packaging considerations in developing medicines for children: oral liquid and powder for constitution.
Campbell GA; Vallejo E
J Pharm Sci; 2015 Jan; 104(1):52-62. PubMed ID: 25393927
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007.
Strickley RG
J Pharm Sci; 2019 Apr; 108(4):1335-1365. PubMed ID: 30447227
[TBL] [Abstract][Full Text] [Related]
20. Development of a novel physico-chemically and microbiologically stable oral solution of flecainide for pediatrics.
Santoveña A; Charola I; Suárez-González J; Teigell-Pérez N; García-van Nood S; Soriano M; Fariña JB
Pharm Dev Technol; 2018 Dec; 23(10):978-985. PubMed ID: 27658320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
